Showing results (1241-1250 of 1,337) with videos related to

Sort By:
Pageof 134
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2007
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical OncologyJulie Gralow, Robert F Ozols, Dean F Bajorin, et al.
Molecular Genetics and Metabolism|October 23, 2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratioM Mokhtarani, G A Diaz, W Rhead, et al.
Nature Medicine|October 24, 2018
A biobank of patient-derived pediatric brain tumor modelsSebastian Brabetz, Sarah E S Leary, Susanne N Gröbner, et al.
The New England Journal of Medicine|May 30, 2014
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinibJennifer A Woyach, Richard R Furman, Ta-Ming Liu, et al.
Molecular Genetics and Metabolism|September 11, 2012
Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disordersM Mokhtarani, G A Diaz, W Rhead, et al.
Nature|August 3, 2018
Author Correction: BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylationSimon Raffel, Mattia Falcone, Niclas Kneisel, et al.
Molecular Genetics and Metabolism|February 20, 2026
From genotype to outcome: Zygosity-specific insights in 63 cases of CLPB-related mitochondrial diseaseOliver Heath, Francisco Del Caño-Ochoa, Safa Baris, et al.
Nature|November 17, 2017
BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylationSimon Raffel, Mattia Falcone, Niclas Kneisel, et al.
Blood|March 22, 2014
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trialStephan Stilgenbauer, Andrea Schnaiter, Peter Paschka, et al.
Acta Neuropathologica|February 24, 2012
Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomasMarcel Kool, Andrey Korshunov, Marc Remke, et al.
Pageof 134